Oct 30, 2009 by Robert SteyerLas Vegas Sands' Inkblot TestThe casino operator beats earnings estimates but keeps investors guessing about financing.
Oct 29, 2009 by Robert SteyerPharma Researchers Need a CureAs the industry changes, Pharmaceutical Product Development and Parexel International struggle.
Oct 28, 2009 by Robert SteyerInvestors Bet on Red for Casino StocksWas Tuesday's mass retreat of casino stocks a one-time event or the beginning of a trend?
Oct 27, 2009 by Robert SteyerPutting the Brakes on Wynn's EarningsDespite beating Wall Street forecasts, Wynn Resorts reveals softness in gambling revenue.
Oct 27, 2009 by Robert SteyerCasinos' Collateral DamageWMS Industries copes with an ailing casino industry and a weak economy.
Oct 23, 2009 by Robert SteyerTaking the Drug Industry's TemperatureCovance and Icon hint at broader pharmaceutical R&D trends.
Oct 22, 2009 by Robert SteyerNibbles Here and There at Forest LabsForest Laboratories banks on its usual strategy to offset generic-drug threats.
Oct 21, 2009 by Robert SteyerWeak Numbers Don't Bother Penn InvestorsInvestors bid up shares of Penn National Gaming even as third-quarter results and fourth-quarter forecasts were disappointing.
Oct 20, 2009 by Robert SteyerMGM Mirage: Partners WantedThe casino's biggest shareholder, Kirk Kerkorian, might seek additional help.
Oct 20, 2009 by Robert SteyerThe Heart Company's Disheartening ForecastBoston Scientific scaled back its full-year forecast, and the market doesn't like it.
Oct 16, 2009 by Robert SteyerBaxter Beats Again -- the Streak Is Alive!The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution.
Oct 15, 2009 by Robert SteyerLittle Discord on Acorda DrugFDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients.
Oct 15, 2009 by Robert SteyerGet Ready for the Next Macau IPOLas Vegas Sands plans Hong Kong IPO; China plans new gambling rules.
Oct 12, 2009 by Robert SteyerHealthy Spinoffs, Happy InvestorsWhen medical companies spin off unwanted divisions, the spinoffs can outperform the parent.
Oct 12, 2009 by Robert SteyerBlackstone Takes Bud for a Thrill RideWill debt muddy Blackstone's purchase of theme parks from Anheuser-Busch InBev?
Oct 9, 2009 by Robert SteyerOn Track for More Gambling?To raise more revenue, the largest U.S. motor sports company wants to build a casino next to its Kansas track.
Oct 8, 2009 by Robert SteyerBeware of Falling 52-Week HighsLook at fundamentals, rather than these tricky numbers.
Oct 7, 2009 by Robert SteyerAcorda's Upcoming ExcitementAcorda is seeking FDA approval for a pill to improve the walking ability of multiple sclerosis patients.
